A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01706536 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

275

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Placebo
DRUG: EP-101 12.5 mcg
DRUG: EP-101 25 mcg
DRUG: EP-101 50 mcg
DRUG: EP-101 100 mcg

Sponsor

Sunovion Respiratory Development Inc.